Prednisone plus azathioprine vs prednisone
Adverse events · bullous pemphigoid
1 finding from 1 review
- no estimate extractedStudies not reportedVery low
Search
What do systematic reviews say?
201 questions · 201 findings · 32 reviews · Skin
No studies found 25 · 12.4%GRADE not reported 7 · 3.5%Very low 61 · 30.3%Low 56 · 27.9%Moderate 49 · 24.4%High 3 · 1.5%
Neoadjuvant immunotherapy (talimogene laherparepvec) vs no neoadjuvant treatment
Adverse events, · stage III and IV cutaneous melanoma
It is very uncertain whether neoadjuvant immunotherapy (talimogene laherparepvec) changes adverse Events, compared with no neoadjuvant treatment (very low certainty).
1 finding from 1 review
- Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes onlyRR 2.84 [0.96, 8.37]1 study · 142 participantsVery low
Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs adjuvant immunotherapy (combined ipilimumab and nivolumab)
Adverse events, · stage III cutaneous melanoma
Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) showed no clear difference in adverse events, compared with adjuvant immunotherapy (combined ipilimumab and nivolumab) (low certainty).
1 finding from 1 review
- Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes onlyRR 1 [0.75, 1.34]1 study · 20 participantsLow
Neoadjuvant treatment vs no neoadjuvant treatment
Adverse events, · stage III and IV cutaneous melanoma
It is very uncertain whether neoadjuvant treatment changes adverse events, compared with no neoadjuvant treatment (very low certainty).
1 finding from 1 review
- Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes onlyRR 1.582 studies · 162 participantsVery low
Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs neoadjuvant immunotherapy (nivolumab)
Adverse events, · stage III and IV cutaneous melanoma
It is very uncertain whether neoadjuvant immunotherapy (combined ipilimumab and nivolumab) changes adverse events, compared with neoadjuvant immunotherapy (nivolumab) (very low certainty).
1 finding from 1 review
- Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes onlyRR 8.73 [1.29, 59]1 study · 23 participantsVery low
Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs neoadjuvant immunotherapy (sequential treatment with ipilimumab then nivolumab)
Adverse events, · stage III cutaneous melanoma
1 finding from 1 review
- Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes onlyno estimate extracted1 study · 86 participantsLow
Neoadjuvant immunotherapy (high dose interferon) plus chemotherapy vs neoadjuvant chemotherapy
Adverse events · stage III and IV cutaneous melanoma
The review found no eligible studies for this question.
1 finding from 1 review
- Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Neoadjuvant targeted treatment (BRAF/MEK inhibition) vs no neoadjuvant treatment
Adverse events, · stage III and IV cutaneous melanoma
1 finding from 1 review
- Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes onlyno estimate extracted1 study · 14 participantsLow
Serlopitant 0.25 mg vs placebo
Adverse events · chronic pruritus of unknown origin
It is very uncertain whether serlopitant 0.25 mg changes adverse events compared with placebo (very low certainty).
1 finding from 1 review
- RR 1.29 [0.75, 2.24]1 study · 127 participantsVery low
Serlopitant 5 mg vs placebo
Adverse events · chronic pruritus of unknown origin
It is very uncertain whether serlopitant 5 mg changes adverse events compared with placebo (very low certainty).
1 finding from 1 review
- RR 1.48 [0.87, 2.5]1 study · 127 participantsVery low
Serlopitant 1 mg vs placebo
Adverse events · chronic pruritus of unknown origin
It is very uncertain whether serlopitant 1 mg changes adverse events compared with placebo (very low certainty).
1 finding from 1 review
- RR 1.45 [0.86, 2.47]1 study · 128 participantsVery low
Biotin vs placebo
Adverse events · infantile seborrhoeic dermatitis (including cradle cap)
1 finding from 1 review
- Interventions for infantile seborrhoeic dermatitis (including cradle cap) 2019 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 39 participantsGRADE not reported
Proprietary products vs placebo
Adverse events · infantile seborrhoeic dermatitis (including cradle cap)
1 finding from 1 review
- Interventions for infantile seborrhoeic dermatitis (including cradle cap) 2019 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 166 participantsVery low
Topical steroid vs comparator
Adverse events · infantile seborrhoeic dermatitis (including cradle cap)
1 finding from 1 review
- Interventions for infantile seborrhoeic dermatitis (including cradle cap) 2019 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 105 participantsVery low
Azoles vs placebo
Adverse events · participants with confirmed toenail onychomycosis
Azole showed no clear difference in adverse events compared with placebo (moderate certainty).
1 finding from 1 review
- RR 1.04 [0.97, 1.12]9 studies · 3441 participantsModerate
Griseofulvin vs azole
Adverse events · participants with confirmed toenail onychomycosis
Griseofulvin probably leads to higher adverse events compared with azole (moderate certainty).
1 finding from 1 review
- RR 2.41 [1.56, 3.73]2 studies · 143 participantsModerate
Griseofulvin vs terbinafine
Adverse events · participants with confirmed toenail onychomycosis
Griseofulvin may leads to higher adverse events compared with terbinafine (low certainty).
1 finding from 1 review
- RR 2.09 [1.15, 3.82]2 studies · 100 participantsLow
Combination terbinafine plus azole vs terbinafine
Adverse events · participants with confirmed toenail onychomycosis
Combination terbinafine plus azole showed no clear difference in adverse events compared with terbinafine monotherapy (low certainty).
1 finding from 1 review
- RR 0.64 [0.34, 1.21]1 study · 176 participantsLow
Azoles vs terbinafine
Adverse events · participants with confirmed toenail onychomycosis
Azole showed no clear difference in adverse events compared with terbinafine (moderate certainty).
1 finding from 1 review
- RR 1 [0.86, 1.17]9 studies · 1762 participantsModerate
Complete cure and adverse events for terbinafine vs placebo
Adverse events · participants with confirmed toenail onychomycosis
Terbinafine showed no clear difference in adverse events compared with placebo (moderate certainty).
1 finding from 1 review
- RR 1.13 [0.87, 1.47]4 studies · 399 participantsModerate